Insight Molecular Diagnostics Inc. is rated Hold due to upcoming catalysts & pending FDA submission for GraftAssureDx. Read ...

Researchers at Dartmouth Hitchcock Medical Center have developed a way to diagnose Lyme disease earlier and more accurately ...

Get key insights from Insight Molecular Diagnostics' Q3 2025 earnings call—FDA progress, $1B market outlook, and innovations in transplant testing.

Certain serious fungal infections occur in regions of the United States with specific environments and are often tied to soil ...

Servier India, the Indian arm of the French pharmaceutical group Servier, has launched a patient-centric biomarker testing ...

Researchers present a molecular test that can identify previously missed cases of Lyme disease and allows for faster diagnosis ...

Natera's integration into OncoEMR enhances workflow efficiency, simplifying the ordering process for precision medicine tests in oncology practices. The integration supports timely treatment decisions ...

Precision medicine relies on biomarker testing to match therapies to specific cancers, yet many patients remain untested due ...

Molecular and genetic testing has become a game-changer in brain tumour care - shaping diagnosis, guiding treatments and opening doors to new therapies.

REDx™FLOQ® is a trademark of Microbix Biosystems Inc. in collaboration with Copan Italia S.p.A. FLOQ® is a trademark of Copan ...

Servier India, a subsidiary of the leading French pharmaceutical company Servier Group, has joined hands with genomic ...

The IMvigor010 trial showed that Signatera-guided treatment with Tecentriq improved disease-free survival and overall ...